Application of different doses of nalmefene hydrochloride combined with hydromorphone in postoperative intravenous controlled analgesia of patients with lumbar fracture internal fixation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063287

Enrollment

Unknown

Registered

2022-09-03

Start date

2022-10-01

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar fractures

Interventions

Group A:Nalmeffe hydrochloride injection was given at 0.75 ug / kg plus 12mg hydromorphone hydrochloride

Group B:Nalmeffe hydrochloride injection was given at 1.5 ug / kg plus 12mg hydromorphone hydrochloride

Group C:12mg hydromorphone hydrochloride alone

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-55 years; 2. ASA I-II; 3. The operation time is less than 2h.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Cognitive dysfunction or communication disorders; 3. Previous or family history of malignant high fever; 4. Known to be allergic to sevoflurane or other anesthetic drugs; 5. Complicated with severe hypertension, diabetes, long-term use of cortisols; 6. History of drug abuse, including but not limited to opioids, amphetamines, methamphetamine, ketamine, etc.; 7. History of postoperative delirium; 8. Liver or renal insufficiency; 9. Abnormal lung function (mainly chronic obstructive pulmonary disease or uncontrolled asthma).

Design outcomes

Primary

Measure	Time frame
Numeric Rating Scale score;	—

Countries

China

Contacts

Public ContactMinjuan Chen

Taizhou Hospital, Zhejiang Province

chenmj@enzemed.com+86 13758628682

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026